雄激素应答元件陷阱DNA抑制PSA基因启动子的作用并诱导LNCaP细胞凋亡(英)

目的：研究雄激素应答元件陷阱DNA（ARE decoy）对前列腺特异抗原（PSA）基因启动子的抑制作用及其对前列腺癌细胞LNCaP细胞生长活性的影响，为前列腺癌的基因治疗寻求新的策略。 方法:联合运用报告基因和陷阱DNA策略，构建含PSA基因5’侧启动子区640 bp DNA的荧光素酶表达载体pGL3-PSA， ARE陷阱DNA共转染前列腺癌细胞株PC3-M。应用双荧光素酶测定系统，检测荧光素酶的表达活性。然后，应用2 mg/L ARE decoy转染LNCaP细胞，通过相差显微镜观察细胞超微结构变化，MTT比色法检测细胞生长活性，DNA ladder和流式细胞技术（FCM）检测细胞凋亡以研究ARE decoy DNA对前列腺癌细胞LNCaP细胞生长活性的影响。同时提取LNCaP细胞核蛋白，应用电泳迁移率变动分析(EMSA)检测ARE decoy DNA与雄激素受体的特异结合。结果:ARE decoy DNA显著抑制报告基因荧光素酶的表达，抑制率可达95%。EMSA显示ARE decoy DNA能特异与核蛋白中雄激素受体结合。LNCaP细胞转染ARE decoy DNA后，镜下观察部分细胞出现凋亡形态学的改变，细胞体外生长受到抑制，染色体DNA凝胶电泳可见明显梯形条带。转染48h的凋亡率为22.4%。 结论:实验表明ARE decoy DNA能竞争结合雄激素受体(AR)，阻断AR的作用而诱导LNCaP细胞凋亡，有可能为前列腺肿瘤的治疗提供新的策略。     

Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling

Melatonin is known to exert antitumour activity in several types of human cancers, but the underlying mechanisms as well as the efficacy of different doses of melatonin are not well defined. Here, we test the hypothesis whether melatonin in the nanomolar range is effective in exerting antitumour activity in vivo and examine the correlation with the hypoxia signalling mechanism, which may be a major molecular mechanism by which melatonin antagonizes cancer. To test this hypothesis, LNCaP human prostate cancer cells were xenografted into seven‐wk‐old Foxn1nu/nu male mice that were treated with melatonin (18 i.p. injections of 1 mg/kg in 41 days). Saline‐treated mice served as control. We found that the melatonin levels in plasma and xenografted tissue were 4× and 60× higher, respectively, than in control samples. Melatonin tended to restore the redox imbalance by increasing expression of Nrf2. As part of the phenotypic response to these perturbations, xenograft microvessel density was less in melatonin‐treated animals, indicative of lower angiogenesis, and the xenograft growth rate was slower (P < 0.0001). These changes were accompanied by a reduced expression of Ki67, elevated expression of HIF‐1α and increased phosphorylation of Akt in melatonin than saline‐treated mice. We conclude that the beneficial effect of melatonin in reducing cancer growth in vivo was evident at melatonin plasma levels as low as 4 nm and was associated with decreased angiogenesis. Higher HIF‐1α expression in xenograft tissue indicates that the antitumour effect cannot be due to a postulated antihypoxic effect, but may stem from lower angiogenesis potential.     

Resveratrol-loaded PLGA nanoparticles mediated programmed cell death in prostate cancer cells

Resveratrol (RL), a natural polyphenol, is known for its diverse biological effects against various human cancer cell lines. But low aqueous solubility, poor bioavailability, and stability limit its efficacy against prostate cancer. In this study polymeric nanoparticles encapsulating resveratrol (RLPLGA) were designed and their cytotoxic and mode of apoptotic cells death against prostate cancer cell line (LNCaP) was determined. Nanoparticles were prepared by solvent displacement method and characterized for particle size, TEM, entrapment efficiency, DSC and drug release study. RLPLGA exhibited a significant decrease in cell viability with 50% and 90% inhibitory concentration (IC₅₀ and IC₉₀) of 15.6?±?1.49 and 41.1?±?2.19?μM respectively against the LNCaP cells. This effect was mediated by apoptosis as confirmed by cell cycle arrest at G1-S transition phase, externalization of phosphatidylserine, DNA nicking, loss of mitochondrial membrane potential and reactive oxygen species generation in LNCaP cells. Furthermore, significantly greater cytotoxicity to LNCaP cells was observed with nanoparticles as compared to that of free RL at all tested concentrations. RLPLGA nanoparticles presented no adverse cytotoxic effects on murine macrophages even at 200?μM. Our findings support the potential use of developed resveratrol loaded nanoparticle for the prostate cancer chemoprevention/ chemotherapy with no adverse effect on normal cells.     

Expression of RANK‐ligand in prostate cancer cell lines

The molecular mediators of bone remodelling, receptor activator of nuclear factor‐kappaB ligand (RANKL), receptor activator of nuclear factor‐kappaB (RANK) and osteoprotegerine (OPG), are believed to be involved in the cellular mechanisms by which tumours metastasize to bone. RANKL is a potent stimulator of osteoclastic bone resorption and is expressed in a variety of tumour cells. We have investigated if the membrane bound form of RANKL is expressed in prostate cancer cell lines, and whether this expression might be regulated by the presence of human osteoblasts. Three prostate cancer cell lines were co‐cultured with human osteoblast‐like cells (hOB) and RANKL expression on cell surface was measured by FACS. We found basal expression of RANKL on the cell surface, and in co‐culture with hOBs the number of cells expressing RANKL was increased between 2.5 and 4 times. These data suggest a signalling mechanism between bone cells and prostate cancer cells that might increase bone resorption and thereby promote bone metastases.     

野生型KLF6对前列腺癌LNCaP细胞的作用

目的:探讨野生型抑癌基因KLF6对前列腺癌LNCaP细胞的生长增殖、细胞周期和侵袭转移能力的影响及其可能的作用机制.方法:利用RT-PCR法克隆目的基因KLF6,并将含KLF6的pEGFP-C1质粒转染入LNCaP细胞.分为转染组和对照组分别进行MTT法观察LNCaP细胞的生长抑制率,流式细胞仪观察细胞周期比例变化和凋亡率,细胞爬片划痕法观察LNCaP细胞的侵袭转移能力变化.结果:转染了野生型抑癌基因KLF6的前列腺癌LNCaP细胞生长抑制率为(31.9±4.7)%,对照组为0%,差异有统计学意义(P＜0.01),细胞周期比例表现为G2/M期减少,G0/G1期比例增加为(75.0±8.8)%,对照组为(55.9±7.1)%,差异有统计学意义(P＜0.05),细胞凋亡峰为(29.3±3.7)% ,对照组为(8.6±0.9)%,差异有统计学意义(P＜0.01);每毫米划痕区内迁移入的细胞数为102.8±15.4,对照组为(192.7±25.2),差异有统计学意义(P＜0.05).结论:野生型抑癌基因KLF6的转染可以明显抑制前列腺癌LNCaP细胞的生长增殖,并诱导其调亡,使其侵袭转移能力下降,其机制可能与野生型抑癌基因KLF6部分地逆转LNCaP细胞的恶性表型有关.     

EGF与miRNA-21联合构建雄激素非依赖性前列腺癌LNCaP亚细胞模型

目的构建雄激素非依赖性的人前列腺癌细胞株LNCaP亚型。方法前期常规RPMI 1640培养基培养LNCaP细胞,然后给予无酚红的RPMI 1640培养基,其中加入10%活性碳/葡聚糖处理的胎牛血清,细胞传代后将10μg/L表皮生长因子（EGF）加入培养基,50 nmol/L miRNA-21类似物转染细胞,长期培养。镜下观察细胞形态变化,MTT检测细胞增殖活性,RT-PCR检测雄激素受体基因扩增情况。结果细胞培养约2.5个月后,LNCaP细胞成功转变为非雄激素依赖的前列腺癌细胞LNCaP亚细胞,细胞增殖能力升高,雄激素受体表达上调。结论体内雄激素依赖性前列腺癌可向雄激素非依赖性前列腺癌转变,而且miRNA-21和EGF对该转变起促进作用。     

Melatonin and prostate cancer cell proliferation: interplay with castration,epidermal growth factor,and androgen sensitivity

BACKGROUND: Potential modulatory effects of melatonin on the proliferation of androgen-sensitive LNCaP and androgen-insensitive PC-3 and DU 145 prostate cancer cells were reported recently. In this study, we investigated the effects of combined melatonin and castration on LNCaP tumor growth in vivo, the interactions between melatonin and epidermal growth factor (EGF) on LNCaP cell proliferation, and melatonin actions on the proliferation of PC-3 and DU 145 cells. METHODS: Tumor development and growth in castrated nude mice inoculated with LNCaP cells or in intact animals inoculated with DU 145 cells, with or without daily melatonin treatment, were monitored by observation and caliper measurement. MT(1) receptor expression in native or transfected prostate cancer cell lines was examined by immunocytochemistry or 2-[(125)I]iodomelatonin binding. Cyclin D1 expression in LNCaP cells was assessed by Western blotting, and cell proliferation was measured by thymidine incorporation and/or cell count. RESULTS: Melatonin treatment was associated with further decreases in LNCaP tumor incidence and growth rate in castrated nude mice. Melatonin and 2-iodomelatonin (a melatonin receptor agonist) attenuated EGF-stimulated increases in LNCaP cell proliferation and cyclin D1 levels. Melatonin had no effect on the proliferation or growth of MT(1) receptor-expressing DU 145 cells, and of PC-3 cells in which MT(1) receptor protein was undetectable. The proliferation of transfected PC-3 cells expressing MT(1) receptor was unaffected by 2-iodomelatonin. CONCLUSION: Together with previous data, the present results indicate synergistic action of melatonin and castration in inhibiting the growth of androgen-sensitive LNCaP tumor. Androgen-sensitive prostate cancer cell proliferation may be modulated by opposite changes in cyclin D1 levels induced by activated MT(1) and EGF receptors. In androgen-insensitive prostate cancer cells, MT(1) receptor-mediated signal transduction may become defective not only through changes in membrane receptor protein expression and/or functions, but also by means of alterations in downstream postreceptor signaling events.